Navigating the Genomic Era: How Whole Genome Sequencing Transforms Kidney Disease Management in Hong Kong

Genomic medicine has rapidly transitioned from laboratory research to clinical practice in recent years. Fueled by whole-genome sequencing (WGS), gene editing, and artificial intelligence, healthcare professionals can now leverage large-scale biobanks to decode human genetic information with unprecedented precision. From diagnosing rare diseases, tailoring personalized medication strategies, to assessing complex disease risks based on polygenic risk scores (PRS), genomic medicine is opening up new possibilities for early intervention and long-term health management.

Looking at the Asia-Pacific region, Hong Kong holds unique advantages in developing genomic medicine thanks to its highly internationalized healthcare and academic systems. As Hong Kong gradually builds a genome database predominantly made up of the Southern Chinese populations, the city has the opportunity to overcome the historical reliance on European ancestry data. This shift will provide a more localized and accurate basis for disease risk assessment and clinical decision-making for Chinese populations worldwide.

The GeneOnline team recently interviewed Dr. Becky Mingyao Ma, a specialist in nephrology and awardee of the HKAM-HKGI Research Excellence Grants in Genomic Medicine, jointly organized by the Hong Kong Genome Institute (HKGI) and the Hong Kong Academy of Medicine (HKAM). During the interview, Dr. Ma shared her insights on Hong Kong’s landscape of genomic medicine and illustrated the applications of WGS technology in the prevention and management of hereditary kidney diseases.

Capitalizing on Centralized Healthcare and the Southern Chinese Data Advantage

Speaking of Hong Kong’s unique position in genomic medicine, Dr. Ma first pointed out the advantages of ethnic homogeneity and a centralized healthcare system. The population of Hong Kong consists mainly of Han Chinese (more than 90%), and such a highly homogeneous population structure is conducive to the establishment of a Chinese-specific genome database, which can minimize the interference caused by differences in genetic backgrounds, and thus more accurately identify pathogenic mutations among Southern Chinese individuals.

Regarding the healthcare system, the Hospital Authority (HA) oversees a vast public hospital network handling nearly 90% of the city’s inpatient demand.  In addition, the territory-wide electronic health record platform established by HA enables authorized healthcare institutions to exchange and access patients’ electronic medical records with their informed consent. This system, together with the Hong Kong Genome Project (HKGP) launched by HKGI, allows researchers to conduct large-scale data analysis and long-term follow-up, thereby precisely identifying disease-causing genetic variants, laying a solid foundation for the development of genomic medicine.

Nevertheless, Dr. Ma also mentioned the challenges ahead. While WGS generates massive volumes of genetic data that places a high demand on computing resources. Beyond infrastructure, translating complex genetic information into clinically actionable treatment plans requires greater involvement from professionals in bioinformatics and genetic counseling. Refining informed consent procedures to adequately address privacy and ethics remains an important focus in the process of clinical translation.

Ending the Diagnostic Odyssey for Kidney Disease Patients

As a specialist in nephrology, Dr. Ma deeply understands how genomic medicine transforms clinical pathways. During the interview, she explained how WGS technology is revolutionizing the diagnosis and treatment of rare hereditary kidney diseases, ending patients’ diagnostic odyssey. 

For many patients suffering from rare or hereditary kidney diseases, finding the root cause of their illnesses can turn into an exhausting journey. They often spend years shuttling between different hospitals and specialists, repeatedly undergoing clinical tests, requiring considerable time, money and energy in the process — yet due to the limitations of medical advancement and various other factors, many see little to no improvement in their condition.

Dr. Ma’s award-winning research clearly demonstrates how WGS can rewrite this narrative. Her team recruited a cohort of 131 patients with kidney disease, 36% of whom reported a family history, and performed WGS analysis, pinpointing the exact causative single-gene variant locus in about 10% of participants.

Unlocking Targeted Precision Care Through WGS

To illustrate the transformative impact of WGS, Dr. Ma shared a compelling clinical case. A patient presenting with classic symptoms of nephrotic syndrome—such as proteinuria, foamy urine, and mild pedal edema—was initially diagnosed with focal segmental glomerulosclerosis (FSGS) based on a kidney biopsy. As the patient’s kidney function declined, steroids were prescribed to control the condition.

According to Dr. Ma, the patient later joined the HKGP, and WGS revealed a pathogenic variant in the COL4A4 gene of this patient, ultimately confirming a diagnosis of Alport syndrome, a rare genetic disorder that primarily affects the tiny blood vessels in the kidneys (glomeruli), which could eventually lead to end-stage renal disease (ESRD).

Armed with this accurate genetic information, the medical team immediately changed the treatment strategy, prescribing specific kidney-protective medications to slow down renal decline. They also initiated screenings for related complications and referred the patient to appropriate specialists. WGS provides a comprehensive diagnosis non-invasively, highlighting how this approach perfectly embodies the patient-centric philosophy of precision medicine.

Beyond Diagnosis: Pharmacogenomics and Polygenic Risk Scores

The power of genomic medicine extends far beyond identifying rare mutations. Dr. Ma highlighted the growing importance of pharmacogenomics, which helps clinicians’ assessments of how individual patients will respond to specific drugs based on their genetic makeup. Taking kidney transplantation as an example, pharmacogenomic information allows doctors to predict patients’ metabolic responses to specific drugs, thus enabling them to optimize dosages, maximize efficacy, and avoid medications that might trigger severe side effects. These personalized care plans are crucial for kidney transplant recipients who require precise immunosuppressant regimens.

Also, genomic information helps doctors perform crucial assessments before transplants. By incorporating WGS analysis alongside standard kidney function assessments, medical teams can prevent a patient from receiving a kidney from a donor who carries a latent pathogenic variant that could cause the disease to surface years later. This not only safeguards the long-term health of the donor, but also ensures that the recipient receives a healthy organ.

Additionally, researchers are exploring polygenic risk scores (PRS) to assess a person’s susceptibility to complex, multifactorial diseases like chronic kidney disease, diabetes, hypertension, and cancer. Unlike single-gene disorders, these conditions result from the cumulative effect of thousands of minor genetic variations. This predictive capability empowers healthcare providers to implement risk stratification, targeted preventative measures, and lifestyle interventions long before irreversible organ damage occurs.

The Power of Multidisciplinary Collaboration

Integrating genomic data into routine clinical care presents a range of operational and coordination complexities. Dr. Ma praised the comprehensive support system provided by the Hong Kong Genome Institute (HKGI). The institute handles everything from sample collection and laboratory operations to provision of a secure Synergistic Research Environment to support genomic research initiatives.

Crucially, HKGI fosters a culture of multidisciplinary collaboration. The institute regularly hosts multi-disciplinary team (MDT) meetings, bringing together frontline clinicians, clinical geneticists, and bioinformatics experts. “These MDT meetings are invaluable,” said Dr. Ma. “They allow us to collectively discuss complex cases and interpret variants of uncertain significance. This direct dialogue breaks down traditional data silos and significantly enhances our diagnostic yield and clinical impact.”

Looking Ahead: Bridging Local Data with Global Research

To further propel the development of precision medicine in Hong Kong, strengthening regional and international cooperation remains crucial. With its world-class healthcare standards and a growing, high-quality Southern Chinese genome database, Hong Kong stands well-positioned to contribute to global scientific progress. “HKGI has already recruited over 52,000 participants for the HKGP and is steadily building a genome database predominantly comprising the Southern Chinese population,” Dr. Ma noted. “In the future, Chinese populations locally and globally will benefit.” She envisions Hong Kong serving as a vital bridge in the genomic era, bringing in top-tier international technologies while simultaneously propelling local scientific achievements onto the global stage.

Concluding the interview, Dr. Ma expressed firm confidence in the future: “Genomic medicine is a marathon. I expect that in the near future, WGS will see widespread use in clinical care, making precise diagnoses and personalized treatments more accessible. I also believe that HKGI will continue supporting professional training for clinicians, empowering medical colleagues to utilize genomic data effectively. At the same time, raising public understanding and acceptance of WGS technology remains essential in building a healthier future for generations to come.”

Author

Richard Chau